<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974220</url>
  </required_header>
  <id_info>
    <org_study_id>DSS16327</org_study_id>
    <nct_id>NCT00974220</nct_id>
  </id_info>
  <brief_title>Effect of Inhaled Fentanyl on Dyspnea and Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Effect of Inhaled Nebulized Fentanyl on Exertional Dyspnea and Exercise Tolerance in Patients With Moderate-to-severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breathing discomfort (dyspnea) and activity limitation are dominant symptoms of chronic
      obstructive pulmonary disease (COPD) and contribute to poor health-related quality of life in
      this population. Several small, uncontrolled studies and published case reports have provided
      evidence that inhaled fentanyl, a powerful pain relieving (opioid) medication, may be used to
      effectively reduce breathing discomfort in patients with advanced disease. However, the
      mechanisms of this improvement remain unclear. Therefore, the investigators plan to conduct
      the first randomized, double-blind, placebo-controlled, crossover study designed to explore
      the possible mechanisms of action of inhaled fentanyl on activity-related dyspnea and
      exercise performance in patients with advanced COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dyspnea Intensity Measured by the 10-point Borg Scale During Cycle Exercise</measure>
    <time_frame>10-minutes post-treatment</time_frame>
    <description>The 10-point Borg scale ranges from 0 &quot;nothing at all&quot; to 10 &quot;maximal/extremely strong&quot; and was used to rate the intensity of dyspnea during exercise; therefore, a decrease in this rating signifies an improvement. Dyspnea intensity was assessed at the highest equivalent standardized time achieved in both post-treatment constant work rate cycle exercise tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cycle Exercise Endurance Time</measure>
    <time_frame>10-minutes post-treatment</time_frame>
    <description>Constant workrate cycle endurance during tests at 75% of the peak incremental workrate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>nebulized 0.9% saline placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nebulized fentanyl citrate (50 mcg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl</intervention_name>
    <description>single dose, 50 mcg of nebulized fentanyl citrate</description>
    <arm_group_label>fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline (placebo)</intervention_name>
    <description>single dose, 0.9% saline solution</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-bronchodilator forced expiratory volume in 1 sec (FEV1) 30-79% predicted,
             FEV1/forced vital capacity (FVC) ratio &lt;70%;

          -  Clinically stable as defined by no changes in medication dosage or frequency of
             administration with no exacerbations or hospital admissions in the preceding 6 weeks;

          -  A cigarette smoking history ≥20 pack-years;

          -  Significant chronic activity-related dyspnea as defined by a Baseline Dyspnea Index
             focal score ≤ 6;

          -  Body mass index (BMI) between 18.5 and 30.0 kg/m2;

          -  Able to perform all study procedures and provide/sign informed consent.

        Exclusion Criteria:

          -  A diffusing capacity of the lung for carbon monoxide (DLCO) &lt;40 %predicted;

          -  Presence of active cardiopulmonary disease other than COPD that could contribute to
             dyspnea and exercise limitation;

          -  Clinical diagnosis of sleep disordered breathing;

          -  A history/clinical evidence of asthma, atopy and/or nasal polyps;

          -  History of allergy or adverse reaction to fentanyl;

          -  Presence of important contraindications to clinical exercise testing, including
             inability to exercise because of neuromuscular or musculoskeletal disease(s);

          -  Use of daytime oxygen or exercise-induced arterial oxygen desaturation to &lt;80% on room
             air;

          -  Use of antidepressant drugs (i.e., monoamine oxidase inhibitors, serotonin reuptake
             inhibitors) in previous 2 weeks;

          -  Use of opioid or pain relieving drugs (e.g., morphine, fentanyl, oxycodone,
             hydromorphone, methadone, levorphanol, codeine, hydrocodone, meperidine) in previous 4
             weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis E O'Donnell, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University and Kingston General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah Dudgeon, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University and Kingston General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Respiratory Investigation Unit, Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <results_first_submitted>September 25, 2013</results_first_submitted>
  <results_first_submitted_qc>November 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2015</results_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Denis O'Donnell</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>inhaled fentanyl</keyword>
  <keyword>dyspnea</keyword>
  <keyword>exercise</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place between February and October 2010. Subjects were recruited from respiratory outpatient clinics and from a database of subjects who had previously taken part in research studies in COPD.</recruitment_details>
      <pre_assignment_details>No enrolled subjects were excluded prior to group assignment.
7 subjects were assigned a treatment order of fentanyl-placebo (2 were withdrawn after period 1) and 9 subjects were assigned a treatment order of placebo-fentanyl (2 were withdrawn after period 1). Therefore, there was complete data from 12 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo - Fentanyl (Order)</title>
          <description>nebulized 0.9% saline placebo in period 1, nebulized fentanyl citrate 50mcg in period 2</description>
        </group>
        <group group_id="P2">
          <title>Fentanyl - Placebo (Order)</title>
          <description>nebulized fentanyl citrate (50 mcg) in period 1, nebulized 0.9% saline placebo in period 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>noncompliant subjects</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo - Fentanyl (Order)</title>
          <description>nebulized saline placebo in period 1, nebulized fentanyl citrate in period 2.</description>
        </group>
        <group group_id="B2">
          <title>Fentanyl - Placebo (Order)</title>
          <description>nebulized fentanyl citrate in period 1, nebulized saline placebo in period 2.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="8"/>
                    <measurement group_id="B2" value="66" spread="10"/>
                    <measurement group_id="B3" value="68" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dyspnea Intensity Measured by the 10-point Borg Scale During Cycle Exercise</title>
        <description>The 10-point Borg scale ranges from 0 &quot;nothing at all&quot; to 10 &quot;maximal/extremely strong&quot; and was used to rate the intensity of dyspnea during exercise; therefore, a decrease in this rating signifies an improvement. Dyspnea intensity was assessed at the highest equivalent standardized time achieved in both post-treatment constant work rate cycle exercise tests.</description>
        <time_frame>10-minutes post-treatment</time_frame>
        <population>Subjects who completed both treatment arms of the crossover study were included in the primary analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>nebulized 0.9% saline placebo</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl</title>
            <description>nebulized fentanyl citrate (50 mcg)</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea Intensity Measured by the 10-point Borg Scale During Cycle Exercise</title>
          <description>The 10-point Borg scale ranges from 0 &quot;nothing at all&quot; to 10 &quot;maximal/extremely strong&quot; and was used to rate the intensity of dyspnea during exercise; therefore, a decrease in this rating signifies an improvement. Dyspnea intensity was assessed at the highest equivalent standardized time achieved in both post-treatment constant work rate cycle exercise tests.</description>
          <population>Subjects who completed both treatment arms of the crossover study were included in the primary analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.5"/>
                    <measurement group_id="O2" value="2.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cycle Exercise Endurance Time</title>
        <description>Constant workrate cycle endurance during tests at 75% of the peak incremental workrate</description>
        <time_frame>10-minutes post-treatment</time_frame>
        <population>Subjects completing both treatment arms were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>nebulized 0.9% saline placebo</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl</title>
            <description>nebulized fentanyl citrate (50 mcg)</description>
          </group>
        </group_list>
        <measure>
          <title>Cycle Exercise Endurance Time</title>
          <description>Constant workrate cycle endurance during tests at 75% of the peak incremental workrate</description>
          <population>Subjects completing both treatment arms were included in this analysis</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" spread="0.56"/>
                    <measurement group_id="O2" value="7.34" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During visit, with appropriate follow-up to resolution of adverse event</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>nebulized 0.9% saline placebo</description>
        </group>
        <group group_id="E2">
          <title>Fentanyl</title>
          <description>nebulized fentanyl citrate (50 mcg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>lightheadedness, dizziness and mild nausea</sub_title>
                <description>Lightheadedness, dizziness and mild nausea was experienced during and immediately after nebulization of the study medication. Symptoms quickly resolved but resulted in discontinuation from the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>severe dyspnea</sub_title>
                <description>Severe dyspnea was experienced during the nebulization of study medication. This resolved quickly after discontinuing nebulization but resulted in withdrawal from the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Denis O'Donnell</name_or_title>
      <organization>Queen's University, Kingston, ON, Canada</organization>
      <phone>1-613-548-2339</phone>
      <email>odonnell@queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

